Thermi, fna ThermiAesthetics, a privately held aesthetic technology company, announced it has secured the final $2 million advance from a debt financing agreement with Cypress Growth Capital. The investment will be used to continue to support operational expansion of the product line and sales growth into new international markets.

Previously Cypress Growth Capital had committed to provide up to $4 million in royalty-based growth capital to Thermi. This investment provided Thermi with $2 million at closing in December 2014, with an additional $2 million available upon Thermi meeting certain conditions.

“This minimally dilutive financing program from Cypress Growth Capital allows the company to continue to focus on the expansion of the product line, continued infrastructure and regulatory investments to further advance international distribution,” said Paul Herchman, CEO.

The Thermi flagship product is the ThermiRF Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue.